3 курс / Фармакология / Диссертация_Куркин_Д_В_Противодиабетические_свойства_и_некоторые

281

P.E. Morales, G. Torres, C. Sotomayor-Flores [et al.] // Biochem Biophys Res

Commun. – 2014. – Vol.446, №1. – P.410-416.

198.Morris, G.P. A comparative study of variables influencing ischemic injury in the longa and koizumi methods of intraluminal filament middle cerebral artery occlusion in mice / G.P. Morris, A.L. Wright, R.P. Tan [et al.] // PLoS One.

–2016. – Vol.11, №2. – P.e0148503.

199.Moynihan, K.A. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice / K.A. Moynihan, A.A. Grimm, M.M. Plueger [et al.] // Cell Metab. – 2005. – Vol.2, №2. – P.105117.

200.Nagayama, K. Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways / K. Nagayama, Y. Kyotani, J. Zhao [et al.] // PLoS One.

–2015. – Vol.10, №9. – P.e0137960.

201.Nassar, N.N. Saxagliptin: a novel antiparkinsonian approach / N.N. Nassar, M.Y. Al-Shorbagy, H.H. Arab, D.M. Abdallah // Neuropharmacology. –

2015. – Vol.89. – P.308-317.

202.O’Rourke, B. Evidence for mitochondrial K+ channels and their role in cardioprotection / B. O’Rourke // Circ Res. – 2004. – Vol.94. – P.420-432.

203.Oballa, R.M. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia / R.M. Oballa, L. Belair, W.C. Black [et al.].// J Med Chem. – 2011. – Vol.54, №14. – P.5082-5096.

204.Odori, S. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function / S. Odori, K. Hosoda, T. Tomita [et al.] // Metabolism. – 2013. – Vol.62. – P.70–78.

205.Overton, H.A. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic

282

agents / H.A. Overton, A.J. Babbs, S.M. Doel [et al.] // Cell Metab. – 2006. –

Vol.3, №3. – P.167-175.

206.Overton, H.A. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity / H.A. Overton, M.C. Fyfe, C. Reynet

//Br J Pharmacol. – 2008. – Vol.153. – P.76–81.

207.Oyama, J. Do incretins improve endothelial function? / J. Oyama, Y. Higashi, K. Node // Cardiovasc Diabetol. – 2014. – Vol.13. – P.21.

208.Park, Y.H. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model / Y.H. Park, H.H. Choi, D.H. Lee [et al.] // Arch Pharm Res. – 2017. – Vol.40, №6. – P.772-782.

209.Pfefferkorn, J.A. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes / J.A. Pfefferkorn // Expert Opin Drug Discov. – 2013. – Vol.8, №3. – P.319-330.

210.Pierce, C.G. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation / C.G. Pierce, S.P. Saville, J.L. Lopez-Ribot // Pathog Dis. – 2014. – Vol.70, №3. – P.423-431

211.Pitocco, D. Oxidative stress, nitric oxide, and diabetes / D. Pitocco, F. Zaccardi, E. Di Stasio // Rev Diabet Stud. – 2010. Vol. 7, № 1. – P. 15-25.

212.Poelje, P.D. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes / P.D. Poelje, S.C. Potter, M.D. Erion // Handb Exp Pharmacol. – 2011. - № 203. – P. 279-301.

213.Poucher, S.M. Effects of saxagliptin and sitagliptin on glycaemic

control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes / S.M. Poucher, S. Cheetham, J. Francis [et al.] // Diabetes Obes Metab. – 2012. – Vol. 14, № 10. – P. 918-926.

214. Purushotham, A. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation / A. Purushotham, T.T. Schug, Q. Xu [et al.] // Cell Metab. – 2009. – Vol.9, №4. –

P.327-338.

283

215.Ramtohul, Y.K. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors / Y.K. Ramtohul, C. Black, C.C. Chan [et al.] // Bioorg Med Chem Lett. – 2010. – Vol.20, №5. – P.1593-1597.

216.Ravassa, S. GLP-1 and cardioprotection: from bench to bedside / S

Ravassa, A Zudaire, J. Díez // Cardiovasc Res. – 2012. – Vol.94, №2. – P.316-323.

217.Ritter, K. G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges / K. Ritter, C. Buning, N. Halland [et al.] // J Med Chem. – 2016. – Vol.59, №8. – P.3579-92.

218.Rohloff, C.M. DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months / C.M. Rohloff, T.R. Alessi, B. Yang [et al.] // J Diabetes Sci Technol. – 2008. – Vol. 2, № 3. – P. 461-467.

219.Saraiva, F. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists / F. Saraiva, A.C. Sposito // Cardiovasc Diabetol. – 2014. – Vol.

13, № 1. – P.142.

220.Seifarth, C. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity / C. Seifarth, B. Schehler, H.J. Schneider // Exp Clin Endocrinol Diabetes. – 2013. – Vol.121, №1. – P.27-31.

221.Shah, U. Recent Advances in the Discovery of GPR119 Agonists. In: Jones RM, editors. New Therapeutic Strategies for Type 2 Diabetes / U. Shah, S. Edmondson, J.W. Szewczyk // Cambridge: Royal Society of Chemistry. - 2012. - P. 177-214.

222.Shigiyama, F. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study / F. Shigiyama, N. Kumashiro, M. Miyagi [et al.] // Cardiovasc Diabetol. – 2017. – Vol.16, №1. – P.84.

223.Shiraishi, D. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation / D. Shiraishi, Y. Fujiwara, Y. Komohara [et al.] // Biochem Biophys Res Commun. – 2012. –

Vol.425, №2. – P.304-308.

284

224.Singh, A.K. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions / A.K. Singh // Indian J Endocrinol Metab. – 2014. – Vol.18, №6. – P.753759.

225.Singh, S.S. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs / S.S. Singh // Curr Drug Metab. – 2006. – Vol.7, №2. –

P.165-182.

226.Smith, S.J. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat / S.J. Smith, S. Cases, D.R. Jensen [et al.] // Nat Genet. – 2000. – Vol.25, №1. – P.87-90.

227.Sun, G. Quantitative analysis of prevention effect of tetrandrine on pancreatic islet beta cells injury in rats / G. Sun, Y. Qi, Q. Pan // Zhonghua Yi Xue Za Zhi. – 1997. – Vol. 77, № 4. – P. 270-273.

228.Szkudelski, T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model / T. Szkudelski // Exp Biol Med (Maywood). - 2012. - Vol. 237, № 5. – P. 481-490.

229.Takeda, S. Identification of G protein-coupled receptor genes from the human genome sequence / S. Takeda, S. Kadowaki, T. Haga et al, // FEBS Lett. –

2002. – Vol.520, №1-3. – P.97-101.

230.Tate, M. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes / M. Tate, A. Chong, E. Robinson [et al.] // Br J Pharmacol. – 2015. – Vol.172, №3. – P.721736.

231.Thorel, F. Conversion of adult pancreatic alpha-cells to beta-cells in diabetic mice / F. Thorel, P.L. Herrera // Med Sci (Paris). – 2010. – Vol. 26, № 11.

–P. 906-909.

232.Tomlinson, B. An overview of new GLP-1 receptor agonists for type 2 diabetes / B. Tomlinson, M. Hu, Y. Zhang [et al.] // Expert Opin Investig Drugs.

–2016. – Vol.25, №2. – P.145-58.

285

233.Vaghasiya, J. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes / J. Vaghasiya, N. Sheth, Y. Bhalodia, R. Manek // Regul Pept. – 2011. – Vol. 166, № 1-3. – P. 48-54.

234.Véniant, M.M. Discovery of a potent, orally active 11βhydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of

(S)-2-((1 S, 2 S, 4 R)-bicyclo [2.2. 1] heptan-2-ylamino)-5-isopropyl-5- methylthiazol-4 (5 H)-one (AMG 221) / M.M. Véniant, C. Hale, R.W. Hungate [et

al.] // J Med Chem. – 2010. – Vol. 53, № 11. – P. 4481-4487.

235.Vetterli, L. Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human islets through a SIRT1-dependent mechanism / L. Vetterli, T. Brun, L. Giovannoni [et al.] // J Biol Chem. – 2011. –

Vol.286, №8. – P.6049-6060.

236.Villanueva, C.J. Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids / C.J. Villanueva, M. Monetti, M. Shih // Hepatology. – 2009. Vol. 50, № 2. – P. 434442.

237.Voss, M.D. Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1) / M.D. Voss, G. Zoller, H. Matter // Eur J Pharmacol. – 2013. –

Vol. 707, № 1. – P. 140-146.

238.Wang, X.M. The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives / X.M. Wang, Y.J. Yang, Y.J. Wu // Cardiovasc Drugs Ther. – 2013. – Vol.27, №4. – P.297-307.

239.Watterson, K.R. Treatment of type 2 diabetes by free Fatty Acid receptor agonists / K.R. Watterson, B.D. Hudson, T. Ulven, G. Milligan // Front Endocrinol (Lausanne). – 2014. – Vol.5. – P.137.

240.Wei, R. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner / R. Wei, S. Ma, C. Wang [et al.] // Am J Physiol Endocrinol Metab. – 2016. –

Vol.310, №11. – P.E947-57.

286

241.Wiernsperger, N.F. Oxidative stress: the special case of diabetes / N.F. Wiernsperger // Biofactors. – 2003. Vol. 19, № 1-2. – P. 11-18.

242.World Health Organization (WHO): Diabetes Mellitus. Report of a WHO Expert Committee. Technical Report Series 310. Geneva: WHO, 1965.

243.World Health Organization: WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva:WHO, 1980.; World Health Organization: Diabetes mellitus. Report of a WHO Study Group. Technical Report Series 727. Geneva: WHO, 1985, p. 727.

244.Wu, H. Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction / H. Wu, H. Chen, P.C. Hu // Clin Lab. 2007;53(5-6):285-295.

245.Xiao-Yun, X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation / X. Xiao-Yun, M. Zhao-Hui, C. Ke [et al.] // Med Sci Monit. – 2011. – Vol.17,

№2.:BR35-41.

246.Xu, J. Molecular insights and therapeutic targets for diabetic endothelial dysfunction / J. Xu, M.H. Zou // Circulation. – 2009. – Vol.120, №13.

–P.1266-1286.

247.Yang, D. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in nondiabetic, normal mice / D. Yang, Y. Nakajo, K. Iihara [et al.] // Brain Res. – 2013.

–Vol.1517. – P.104-113.

248.Yang, R. Leptin signaling and obesity: cardiovascular consequences / R. Yang, L.A. Barouch // Circ Res. – 2007. – Vol.101, №6. – P.545-559.

249.Yoshida, S. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function / S. Yoshida, T. Ohishi, T. Matsui [et al.] // Diabetes Obes Metab. – 2011. – Vol.13, №1. – P.3441.

250.Zeng, Y. The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting

287

Sirt1 and Sirt3 expression / Y. Zeng, K. Yang, F. Wang [et al.] // Exp Eye Res. – 2016. – Vol.151. – P.203-211.

251. Zhan, Y. Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs) – induced apoptosis / Y. Zhan, H.L. Sun, H. Chen [et al.] // Med Sci Monit. – 2012. – Vol.18,

№7. – P.286-291.

252. Zhang, D. Potential roles of GPR120 and its agonists in the management of diabetes / D. Zhang, P.S. Leung // Drug Des Devel Ther. – 2014. – Vol.8. – P.1013-1027.

253.Zhang, M. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice / M. Zhang, Y. Feng, J. Wang // PLoS One. – 2013. – Vol. 8, № 5. – P. e63861.

254.Zhang, X.D. Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice / X.D. Zhang, J.W. Yan, G.R. Yan [et al.] // Acta Pharmacol Sin. –

2010. – Vol.31, №11. – P.1470-1477.

255.Zhao, L. Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKAdependent pathway / L. Zhao, A.Q. Li, T.F. Zhou [et al.] // Am J Physiol Cell Physiol. – 2014. – Vol.307, №12. – P.1130-1141.

256.Zhao, T. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts / T. Zhao, P. Parikh, S. Bhashyam [et al.] // J Pharmacol Exp Ther. – 2006. – Vol.317,

№3. – P.1106-1113.

257.Zhao, X. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells / X. Zhao, G. Liu, H. Shen [et al.] // Int J Mol Med. – 2015. – Vol. 35, № 3. – P. 684-692.

258.Zhu, H. The Neuroprotection of Liraglutide Against Ischaemiainduced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways

/H. Zhu, Y. Zhang, Z. Shi [et al.] // Sci Rep. – 2016. – Vol.6. – P.26859.

288

290